Higher-risk MDS and AML: How new guidelines are changing diagnosis, classification and management

The 2022 updates of international guidelines affect diagnosis, classification and management of HR-MDS and AML.
Get up-to-date on their impact on clinical practice with expert perspectives.
Watch now: touchhaematology.com/educatio...
With Prof. Andrew Wei, Prof. Agnieszka Wierzbowska and Prof. Gert Ossenkoppele.
--------
This activity is supported by an independent medical education grant from Novartis and is provided by touchIME.

[@amybradley5821]

Does it really matter as the treatments are mostly the same. I refuse to have a bone marrow aspiration. They are saying MDS but treatment seems the same. I would never consider a BMT so just treat as things come up. For now I have low white and platelets and reds are about to go below normal. I don’t see treatments very different